東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Uncertainty in pharmacology = episte...

LaCaze, Adam.

FindBook

Google Book

Amazon

博客來

Uncertainty in pharmacology = epistemology, methods, and decisions /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Uncertainty in pharmacology/ edited by Adam LaCaze, Barbara Osimani.
其他題名:	epistemology, methods, and decisions /
其他作者:	LaCaze, Adam.
出版者:	Cham :Springer International Publishing : : 2020.,
面頁冊數:	xiii, 470 p. :ill., digital ;24 cm.
內容註:	Part I. Epistemology -- 1. Defining Aspects of Mechanisms: Evidence-Based Mechanism (Evidence for a Mechanism), Mechanism-Based Evidence (Evidence from a Mechanism), and Mechanistic Reasoning -- 2. Causal Insights from Failure: Post-Marketing Risk Assessment of Drugs as aWay to Uncover Causal Mechanisms -- 3. Extrapolating from Model Organisms in Pharmacology -- 4. "Mechanistic Versus Statistical Extrapolation in Preclinical Research in Psychiatry: Challenging the Received View" -- 5. Analogy-Based Inference Patterns in Pharmacological Research -- 6. "In Silico Clinical Trials: a Possible Response to Complexity in Pharmacology" -- 7. "Uncertainty in Drug Discovery: Strategies, Heuristics and Technologies" -- 8. "Caught in the Amber": a Sketch of Chemical Underdetermination -- Part II. Methods -- 9. A Millian Look at the Logic of Clinical Trials -- 10. "Learning by Difference: Placebo Effects and Specific Efficacy in Pharmacological RCTs" -- 11. "An Evidence-Hierarchical Decision Aid for Ranking in Evidence-Based Medicine" -- 12. "Assessing Drug Safety Assessment: Metformin Associated Lactic Acidosis" -- 13. Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer's Measurement -- 14. "Modelling Individual Response to Treatment and its Uncertainty: a Review of Statistical Methods and Challenges for Future Research" -- Part III. Decisions -- 15. Values in Pharmacology -- 16. "Humbug, the Council of Pharmacy and Chemistry, and the Origin of "the Blind Test" of Therapeutic Efficacy" -- 17. On the Normative Foundations of Pharmaceutical Regulation -- 18. After Disclosure -- 19. Sex, Drugs, and how to Deal with Criticism-The Case of Flibanserin.
Contained By:	Springer eBooks
標題:	Pharmacology. -
電子資源:	https://doi.org/10.1007/978-3-030-29179-2
ISBN:	9783030291792

Uncertainty in pharmacology = epistemology, methods, and decisions /
Uncertainty in pharmacologyepistemology, methods, and decisions /[electronic resource] :edited by Adam LaCaze, Barbara Osimani. - Cham :Springer International Publishing :2020. - xiii, 470 p. :ill., digital ;24 cm. - Boston studies in the philosophy and history of science,v.3380068-0346 ;. - Boston studies in the philosophy and history of science ;v.338..

Part I. Epistemology -- 1. Defining Aspects of Mechanisms: Evidence-Based Mechanism (Evidence for a Mechanism), Mechanism-Based Evidence (Evidence from a Mechanism), and Mechanistic Reasoning -- 2. Causal Insights from Failure: Post-Marketing Risk Assessment of Drugs as aWay to Uncover Causal Mechanisms -- 3. Extrapolating from Model Organisms in Pharmacology -- 4. "Mechanistic Versus Statistical Extrapolation in Preclinical Research in Psychiatry: Challenging the Received View" -- 5. Analogy-Based Inference Patterns in Pharmacological Research -- 6. "In Silico Clinical Trials: a Possible Response to Complexity in Pharmacology" -- 7. "Uncertainty in Drug Discovery: Strategies, Heuristics and Technologies" -- 8. "Caught in the Amber": a Sketch of Chemical Underdetermination -- Part II. Methods -- 9. A Millian Look at the Logic of Clinical Trials -- 10. "Learning by Difference: Placebo Effects and Specific Efficacy in Pharmacological RCTs" -- 11. "An Evidence-Hierarchical Decision Aid for Ranking in Evidence-Based Medicine" -- 12. "Assessing Drug Safety Assessment: Metformin Associated Lactic Acidosis" -- 13. Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer's Measurement -- 14. "Modelling Individual Response to Treatment and its Uncertainty: a Review of Statistical Methods and Challenges for Future Research" -- Part III. Decisions -- 15. Values in Pharmacology -- 16. "Humbug, the Council of Pharmacy and Chemistry, and the Origin of "the Blind Test" of Therapeutic Efficacy" -- 17. On the Normative Foundations of Pharmaceutical Regulation -- 18. After Disclosure -- 19. Sex, Drugs, and how to Deal with Criticism-The Case of Flibanserin.

This volume covers a wide range of topics concerning methodological, epistemological, and regulatory-ethical issues around pharmacology. The book focuses in particular on the diverse sources of uncertainty, the different kinds of uncertainty that there are, and the diverse ways in which these uncertainties are (or could be) addressed. Compared with the more basic sciences, such as chemistry or biology, pharmacology works across diverse observable levels of reality: although the first step in the causal chain leading to the therapeutic outcome takes place at the biochemical level, the end-effect is a clinically observable result-which is influenced not only by biological actions, but also psychological and social phenomena. Issues of causality and evidence must be treated with these specific aspects in mind. In covering these issues, the book opens up a common domain of investigation which intersects the deeply intertwined dimensions of pharmacological research, pharmaceutical regulation and the related economic environment. The book is a collective endeavour with in-depth contributions from experts in pharmacology, philosophy of medicine, statistics, scientific methodology, formal and social epistemology, working in constant dialogue across disciplinary boundaries.

ISBN: 9783030291792

Standard No.: 10.1007/978-3-030-29179-2doiSubjects--Topical Terms:

634543
Pharmacology.

LC Class. No.: RM301 / .U53 2020

Dewey Class. No.: 615

Uncertainty in pharmacology = epistemology, methods, and decisions /
LDR:04056nmm a2200337 a 4500 001 2216660
003 DE-He213
005 20200220152055.0
006 m d
007 cr nn 008maaau
008 201120s2020 sz s 0 eng d
020 $a 9783030291792 $q (electronic bk.)
020 $a 9783030291785 $q (paper)
024 7 $a 10.1007/978-3-030-29179-2 $2 doi
035 $a 978-3-030-29179-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301 $b .U53 2020
072 7 $a HP $2 bicssc
072 7 $a MED050000 $2 bisacsh
072 7 $a QD $2 thema
082 0 4 $a 615 $2 23
090 $a RM301 $b .U54 2020
245 0 0 $a Uncertainty in pharmacology $h [electronic resource] : $b epistemology, methods, and decisions / $c edited by Adam LaCaze, Barbara Osimani.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a xiii, 470 p. : $b ill., digital ; $c 24 cm.
490 1 $a Boston studies in the philosophy and history of science, $x 0068-0346 ; $v v.338
505 0 $a Part I. Epistemology -- 1. Defining Aspects of Mechanisms: Evidence-Based Mechanism (Evidence for a Mechanism), Mechanism-Based Evidence (Evidence from a Mechanism), and Mechanistic Reasoning -- 2. Causal Insights from Failure: Post-Marketing Risk Assessment of Drugs as aWay to Uncover Causal Mechanisms -- 3. Extrapolating from Model Organisms in Pharmacology -- 4. "Mechanistic Versus Statistical Extrapolation in Preclinical Research in Psychiatry: Challenging the Received View" -- 5. Analogy-Based Inference Patterns in Pharmacological Research -- 6. "In Silico Clinical Trials: a Possible Response to Complexity in Pharmacology" -- 7. "Uncertainty in Drug Discovery: Strategies, Heuristics and Technologies" -- 8. "Caught in the Amber": a Sketch of Chemical Underdetermination -- Part II. Methods -- 9. A Millian Look at the Logic of Clinical Trials -- 10. "Learning by Difference: Placebo Effects and Specific Efficacy in Pharmacological RCTs" -- 11. "An Evidence-Hierarchical Decision Aid for Ranking in Evidence-Based Medicine" -- 12. "Assessing Drug Safety Assessment: Metformin Associated Lactic Acidosis" -- 13. Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer's Measurement -- 14. "Modelling Individual Response to Treatment and its Uncertainty: a Review of Statistical Methods and Challenges for Future Research" -- Part III. Decisions -- 15. Values in Pharmacology -- 16. "Humbug, the Council of Pharmacy and Chemistry, and the Origin of "the Blind Test" of Therapeutic Efficacy" -- 17. On the Normative Foundations of Pharmaceutical Regulation -- 18. After Disclosure -- 19. Sex, Drugs, and how to Deal with Criticism-The Case of Flibanserin.
520 $a This volume covers a wide range of topics concerning methodological, epistemological, and regulatory-ethical issues around pharmacology. The book focuses in particular on the diverse sources of uncertainty, the different kinds of uncertainty that there are, and the diverse ways in which these uncertainties are (or could be) addressed. Compared with the more basic sciences, such as chemistry or biology, pharmacology works across diverse observable levels of reality: although the first step in the causal chain leading to the therapeutic outcome takes place at the biochemical level, the end-effect is a clinically observable result-which is influenced not only by biological actions, but also psychological and social phenomena. Issues of causality and evidence must be treated with these specific aspects in mind. In covering these issues, the book opens up a common domain of investigation which intersects the deeply intertwined dimensions of pharmacological research, pharmaceutical regulation and the related economic environment. The book is a collective endeavour with in-depth contributions from experts in pharmacology, philosophy of medicine, statistics, scientific methodology, formal and social epistemology, working in constant dialogue across disciplinary boundaries.
650 0 $a Pharmacology. $3 634543
650 1 4 $a Philosophy of Medicine. $3 894449
650 2 4 $a Theory of Medicine/Bioethics. $3 894447
700 1 $a LaCaze, Adam. $3 3449144
700 1 $a Osimani, Barbara. $3 3449145
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Boston studies in the philosophy and history of science ; $v v.338. $3 3449146
856 4 0 $u https://doi.org/10.1007/978-3-030-29179-2
950 $a Religion and Philosophy (Springer-41175)